Digital Integration Initiatives

About Embecta

Embecta is a global medical device company exclusively dedicated to diabetes care, formed via a 2022 spin-off from Becton, Dickinson and Company (BD). Its mission is to leverage a 100-year heritage in injection devices to enhance the daily lives of over 30 million people with diabetes worldwide through its core products: insulin pen needles and syringes. The company's strategy is to focus its R&D and commercial resources entirely on advancing mechanical insulin delivery, improving patient comfort, and expanding access in global markets. As a newly independent public entity, Embecta aims to drive growth by deepening its patient-centric innovation and operational execution.

Therapeutic Areas